Compare NVGS & CERT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NVGS | CERT |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Retail: Computer Software & Peripheral Equipment |
| Sector | Consumer Discretionary | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | N/A | 2020 |
| Metric | NVGS | CERT |
|---|---|---|
| Price | $17.31 | $9.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $21.50 | $14.50 |
| AVG Volume (30 Days) | 298.0K | ★ 2.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | ★ 33.99 | N/A |
| EPS | ★ 1.50 | 0.07 |
| Revenue | ★ $578,158,000.00 | $415,551,000.00 |
| Revenue This Year | $2.77 | $10.82 |
| Revenue Next Year | $0.18 | $6.77 |
| P/E Ratio | ★ $11.73 | $137.19 |
| Revenue Growth | 2.46 | ★ 11.47 |
| 52 Week Low | $10.55 | $8.03 |
| 52 Week High | $18.29 | $15.69 |
| Indicator | NVGS | CERT |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 43.45 |
| Support Level | $17.68 | $8.95 |
| Resistance Level | $18.07 | $9.42 |
| Average True Range (ATR) | 0.39 | 0.39 |
| MACD | -0.12 | 0.14 |
| Stochastic Oscillator | 16.49 | 59.88 |
Navigator Holdings Ltd owns and operates liquefied gas carriers, which include a fleet of handysize liquefied gas carriers. The company also owns a share in an ethylene export marine terminal at Morgan's Point, Texas on the Houston Ship Channel (the Ethylene Export Terminal) through a joint venture (the Export Terminal Joint Venture). Company play a vital role in theglobalised liquefied gas supply chain, providing gas transportation solutions for energy companies, industrial users and commodity traders.
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval and increase patient access to medicines. The company has its business presence in the Americas which is also it key revenue generating market, EMEA and Asia Pacific region.